Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
TAKDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 11, 2025 | $0.32 | 2025-09-30 | 2025-09-30 |
| July 7, 2025 | $0.34 | 2025-03-31 | 2025-03-31 |
| December 12, 2024 | $0.33 | 2024-09-30 | 2024-09-30 |
| July 8, 2024 | $0.29 | 2024-03-27 | 2024-03-28 |
| December 11, 2023 | $0.32 | 2023-09-28 | 2023-09-29 |
Dividends Summary
- Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) has issued 14 dividend payments over the past 6 years
- The most recent dividend was paid 9 days ago, on December 11, 2025
- The highest dividend payed out to investors during this period was $0.43 per share
- The average dividend paid during this period was $0.36 per share.
Company News
Over 20 pharmaceutical companies are developing new treatments for celiac disease, moving beyond the current gluten-free diet management approach. Clinical trials are exploring innovative therapies targeting various mechanisms to improve patient outcomes.
Takeda Pharmaceutical has entered a multi-year research collaboration with Nabla Bio, utilizing their generative AI platform for antibody design, with potential payments exceeding $1 billion.
Protagonist Therapeutics reported Q2 2025 financial results, highlighting progress in clinical pipeline with rusfertide and icotrokinra drug candidates, while experiencing lower-than-expected revenue but maintaining strong cash reserves through 2028.
Per argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication with a novel mechanism of action to treat chronic inflammatory demyelinating polyneuropathy.
